Skip to main content
. Author manuscript; available in PMC: 2016 Aug 15.
Published in final edited form as: J Immunol. 2015 Jul 10;195(4):1591–1598. doi: 10.4049/jimmunol.1500451

FIGURE 5.

FIGURE 5

Rapamycin treatment partially corrects CD8 T cell recall defects in CD4−/− mice. The mice were injected i.v. with bone marrow derived dendritic cell pulsed with SIY peptides (BMDC-SIY) 37 dpi (Fig. 4A). The numbers of T cells specific for SIY/Kb and expressing IFN-γ were analyzed 5 days later. (A–E) The number of SIY/Kb-specific CD8 T cells in the lung (A), spleen (B), mediastinal LN (C) and inguinal LN (D) of CD4−/− and WT mice with or without rapamycin treatment. (E) The number of IFN-γ+ CD8 T cells in the spleen of CD4−/− and WT mice with or without rapamycin treatment. Error bars: SEM from 5–6 mice per group from one of three representative experiments. * P<0.05.